Catherine Hartmann

Secretary General of the European COPD Coalition

Member of the European Chronic Disease Alliance8th EU Patients Rights Day 12-13 May

Chronic diseases’ networks added value in policy making Different successful models to networking

The European Chronic Disease Alliance (ECDA)

The European Chronic Disease Alliance (ECDA)

ECDA – a key stakeholder that brings value

Cancer

CVDs

Allergies

COPD & asthma

Kidneydiseases

DiabetesHCPS

Patients

Care takers

Liverdiseases

Researchers

ECDA’s structure

• Association de fait• Full and Associate members• Unanimously adopted decisions• Professional secretariat

Why use advocacy?

The burden of chronic diseases

Benefits of Stakeholders involvement in response to Chronic Diseases

• For the EU policymakers

• For the EU stakeholders

What ECDA does

Drafting white papers and statements, providing input to consultations, sending letters, taking part in an EU Funded project, press articles – advocacy tools are numerous

What ECDA does - 2 Meeting with key EU officials- and in particular, directors & heads of unit at the DG SANCO:

DG SANCO representatives

EU Commissioner for health, Tonio Borg

EU health award, Gastein 2010

ECDA Call for Action

Urgent political action is needed to reduce the human, social and economic burden of chronic diseases.

We, as ECDA, representing millions of patients and over 100,000 health professionals call for:

EU framework on Chronic Diseases

EU a

dded

-val

ue

in collaboration with relevant stakeholders

by 2017Intervene on health

determinants

Incorporate targets

Invest in prevention

Strengthen cooperation

Encourage citizens to make healthy choices

Ensure availability of

comparable data

Enhance cooperation on

research

Strengthen monitoring and

evaluation

To recap – a Key Political Momentum for CDsECDA five key Recommendations1. The EU must adopt a comprehensive framework on chronic diseases that

leverages EU and MS regulatory competences and resources in all policies.2. The EU must support MS in adapting health care systems to respond to the

growing burden of chronic diseases, ageing population and increasing prevalence of co-morbidities.

3. The EU should introduce population-wide measures to reduce the key risk factors.

4. Successful and proven harm reduction policies should also remain in place in the MS and be properly resourced.

5. Monitoring and evaluating actions for chronic diseases should encompass establishing EU-wide surveillance and screening programmes (EU registries).

Thank youECDA

Rue du Luxembourg 22-24 I 1000 Brussels | BelgiumPhone: +32 2 213 13 12

E-mail: info@alliancechronicdiseases.orgwww.alliancechronicdiseases.org